Arca
Skip to content
Tools
Tools

Medulloblastoma

Drug research and approvals for medulloblastoma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 21, 2026, 40 studies of medulloblastoma are recruiting on ClinicalTrials.gov, Health Canada has authorized 9 drug trials for it since 2013, and FDA has 0 approved and 4 open orphan designations naming it.

  • Recruiting worldwide: 40
  • Trials authorized in Canada: 9
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting now

Newest posted first, of 40 recruiting on ClinicalTrials.gov ↗

Drug pipeline

Each drug at the furthest stage it has reached for this condition, from ChEMBL's drug indications

Approved 1

Phase 3 12

Phase 2 12 of 19

Phase 1 or earlier 11

How its trials ended

210 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 44 whose ending is known, 27% met their primary endpoint, 9% missed it and 64% stopped early.

  • Completed, result not reported8139%
  • Ongoing7033%
  • Stopped: other or unclear157%
  • Status unknown157%
  • Met its primary endpoint126%
  • Stopped: enrollment or feasibility52%
  • Missed its primary endpoint42%
  • Stopped: sponsor or business decision42%
  • Stopped: lack of efficacy31%
  • Stopped: funding1<1%

Trials authorized in Canada

Newest first; search them all in Canada trials
Jul 7, 2025A phase 3 study of sodium thiosulfate for reduction of cisplatin-induced ototoxicity in children with average-risk medulloblastoma and reduced therapy in…Sodium thiosulfateChildrens Oncology GroupOngoing
Jan 23, 2025Phase II trial of eflornithine/dfmo as maintenance therapy for molecular high risk/very high risk and relapsed/refractory medulloblastomaEflornithine (DFMO)Beat Childhood CancerOngoing
Oct 4, 2022A phase I study of savolitinib in recurrent, progressive, or refractory medulloblastoma, high-grade glioma, diffuse intrinsic pontine glioma, and CNS tumors…SavolitinibPediatric Brain Tumour ConsortiumClosed
Feb 15, 2022Phase III randomized double-blind placebo-controlled trial of metformin for cognitive recovery and white matter growth in paediatric patients with a brain…MetforminHospital for Sick ChildrenOngoing
Oct 31, 2017A phase 2 study of reduced therapy for newly diagnosed average-risk wnt-driven medulloblastoma patientsCyclophosphamide / Cisplatin / VincristineChildrens Oncology GroupOngoing
May 2, 2017Newly diagnosed children (less than 10 years old) with medulloblastoma and other central nervous system embryonal tumors: clinical and molecular risk-tailored…Carboplatin / Cisplatin / Cyclophosphamide/ Etoposide / Etoposide phosphate /…Next ConsortiumOngoing
May 22, 2015A clinical and molecular risk-directed therapy for newly diagnosed medulloblastomaVismodegib/ Amifostine/ Cisplatin/ Cyclophosphamide/ Pemetrexed/ Gemcitabine/…St Jude Childrens Research HospitalOngoing
Jan 31, 2014A phase II study for the treatment of non-metastatic nodular desmoplastic medulloblastoma in children less than 4 years of ageVincristine/ Cyclophosphamide/ Methotrexate/ Leucovorin/ Etoposide/ Etoposide…Childrens Oncology GroupClosed
Dec 20, 2013Placebo controlled double blind crossover trial of metformin for brain repair in children treated with cranial-spinal radiation for medulloblastomaMetforminHospital for Sick ChildrenClosed

FDA orphan designations

Approved first, then open designations, newest first
Dec 15, 2021SilmitasertibTreatment of MedulloblastomaSenhwa Biosciences, Inc.Designated
May 9, 2019Genetically engineered herpes simplex virusTreatment of medulloblastomaAettis, Inc.Designated
Jan 17, 20172-Amino-4-[11C]methylsulfanyl-butanoic acid, l-[S…Diagnostic agent for the Clinical Management of MedulloblastomaAdvanced Imaging Projects, LLCDesignated
Mar 10, 20161,2:5,6-dianhydrogalactitolTreatment of medulloblastoma.DelMar Pharmaceuticals, Inc.Designated

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.